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Abstract 
Non-transferrin-bound iron (NTBI) is a heterogeneously speciated plasma iron, typically 
detectable when transferrin saturation (TfSat) exceeds 75%. Here we examine factors 
affecting NTBI levels by a recently discovered direct chelator-based (CP851) fluorescent 
bead-linked flow-cytometric assay (bead-NTBI), compared with the established indirect 
nitrilotriacetate (NTA) assay in 122 iron-overloaded patients, including 64 on recent iron 
chelation therapy and 13 healthy volunteers. Both methods correlated (r=0.57, p<0.0001) but 
with low agreement, attributable to two major factors: (1) the NTA method, unlike the bead 
method, is highly dependent on TfSat, with NTBI under-estimation at low TfSat and over-
estimation once Tf is saturated, (2) the bead method detects <3-fold higher values than the 
NTA assay in patients on recent deferiprone-containing chelation due to greater detection of 
chelate complexes but lower values for patients on deferasirox. The optimal timing of sample 
collection relative to chelation dosing requires further study. Patients with splenectomy, high 
storage iron and increased erythropoiesis had greater discrepancy between assays, consistent 
with differential access by both methods to the NTBI pools associated with these clinical 
variables. The bead-NTBI assay has advantages over the NTA assay, being less dependent on 
TfSat, hence of less tendency for false-negative or false-positive values at low and high 
TfSat, respectively. 
 
Keywords: iron, iron overload, iron biochemistry, thalassaemia, erythropoiesis, NTBI, assay 
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Introduction 
Plasma non-transferrin-bound iron (NTBI), first described in 19781, is a pathological iron 
pool detectable when Tf saturation exceeds 75%2–4. NTBI appears when iron influx into the 
plasma compartment exceeds iron efflux, e.g. with iron overload, ineffective erythropoiesis, 
or decreased transferrin iron clearance in erythroid hypoplasia5. NTBI is considered the main 
conduit of hepatic6–8 and extra-hepatic9–12 iron loading of tissues, under haemosiderotic 
conditions. Quantitating NTBI is of value in understanding NTBI generation under different 
pathophysiological settings5 but can also be potentially useful in the management of iron-
overloaded patients. However using established methods for NTBI quantitation, clear 
consensus and guidelines on how to use NTBI measurement in patient management have yet 
to emerge. This is partly because NTBI is multi-speciated, consisting of a range of iron-
citrate13,14, albumin-bound complexes13, glycated protein-iron complexes15,16 or iron-chelate 
complexes in recently chelated patients17. Consequently it is unlikely that NTBI assays 
relying on different principles will measure different NTBI species to the same extent. Hence 
a consistent pattern of association between NTBI values and clinical outcomes has yet to 
emerge.  
There is therefore a need to identify a robust and well-characterised NTBI assay that can be 
applied in a standardised manner in the management of iron–overloaded patients. A range of 
NTBI methods used previously differ considerably in their detection principles and in 
reported reference ranges18. The most long-standing and frequently reported NTBI method19 
involves iron capture from NTBI by a high concentration of a low affinity/specificity iron 
chelator, nitrilotriacetic acid (NTA, 80mM), followed by ultrafiltration and detection of 
NTA-iron by HPLC2,19 or spectrophotometrically3. Another approach is measuring NTBI 
indirectly by quantifying the redox-active subset of NTBI, which has been termed the ‘labile 
plasma iron’ (LPI) assay20.  A further approach is measuring the directly chelatable iron 
(DCI) with a fluorophore-labelled high-affinity chelator18,21,22 but background fluorescence in 
plasma may interfere with data interpretation. Most recently, an adaptation of this approach 
was described, using a high-affinity fluorescent chelator CP851, covalently linked to 
magnetic beads with fluorescence signal separated flow-cytometrically from plasma 
autofluorescence23. This potentially circumvents the auto-fluorescence problem in the plasma 
sample and problems related to indirect capture of NTBI by NTA.   
The initial paper describing the bead method23 examined only 30 patients and did not 
therefore explore the variables affecting the agreement between the NTA and the bead 
method systematically. In particular, the effects of TfSat, chelators, splenectomy status and 
underlying diagnosis were not explored. A recent round robin18 comparing various NTBI and 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
 
 
  
4
 Factors affecting novel bead-NTBI assay 
 
  
LPI methods on 60 patients, reported their overall lack of agreement in absolute values 
despite similar correlations, but did not specifically look at the agreement between these two 
methods and could not therefore comment on the possible reasons for their poor agreement. 
Here, we compare levels of NTBI detected by this assay with the NTA method in various 
clinical conditions, including 122 iron-overloaded patients with approximately half (n=64) 
receiving regular chelation therapy. Part of this work was presented as Abstract no. 241 at 
BioIron Conference Sep 6-10, 2015 in Zhejiang University, China. 
Materials and Methods 
Patients 
122 clinical blood samples from iron-overloaded patients and 13 healthy volunteers, obtained 
from 3 hospitals (affiliations 2, 4 and 5), were analysed using the CP851-NTBI assay and 
NTA-NTBI assay. Diagnoses included are listed in Table I. Ethical approval was obtained 
for the study at the respective institutions where blood samples were collected and patients 
signed informed consent forms before sample collection. 
NTBI assays 
NTA-NTBI assay 
The NTA-NTBI method previously described19 was adopted with minor modifications. 
Briefly, 0.02mL of 800mM NTA (at pH=7) was added to 0.18mL serum and allowed to stand 
for 30min at 22oC. The solution was ultrafiltered using Whatman Vectaspin 
ultracentrifugation devices (30 kDa) at 12320g and the ultrafiltrate (0.02mL) injected directly 
onto an HPLC column (ChromSpher-ODS, 5µM, 100x3mm, glass column fitted with an 
appropriate guard column) equilibrated with 5% acetonitrile and 3mM DFP in 5mM MOPS 
(pH=7.8). The NTA-iron complex then exchanges to form the DFP–iron complex detected at 
460nm by a Waters 996 PDA. Injecting standard concentrations of iron prepared in 80mM 
NTA generated a standard curve. The 800mM NTA solution used to treat the samples and 
prepare the standards is treated with 2µM iron to normalize the background iron that 
contaminates reagents. This means that the zero standard gives a positive signal since it 
contains the added background iron as an NTA–complex. When unsaturated transferrin is 
present in sera, this additional background iron can be donated to vacant transferrin sites 
resulting in a loss of the background signal and yielding a negative NTBI value. 
CP851 bead-NTBI assay 
The standards for this assay were prepared as follows: 1mM iron-NTA complex (1:2.5 molar 
ratio), prepared from 100mM NTA and 18mM atomic absorption standard iron solution, was 
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diluted with MilliQ water to a final concentration (f.c.) between 0-100µM. For the standard 
curve, 120µL quantities of probe-labelled bead suspensions were incubated with 20µL of 
buffered NTA-iron solutions of known concentration for 20min at room temperature, with 
subsequent addition of 20µL normal control serum (without free iron) and 40µL 
paraformaldehyde (10% in MOPS) at 2% f.c. The suspensions in sealed 96-well plates were 
incubated at 37oC for 16h with shaking before fluorescence measurement by flow-cytometry. 
For serum samples of unknown iron concentrations, 140µL quantities of beads were 
incubated with 20µL of serum samples for 20min, with subsequent addition of 40µL 
paraformaldehyde at 2% (f.c.). In this study, we used chelatable fluorescent beads (CFB) with 
normal human mixed serum as control to set up the fluorescence at 100% and the relative 
fluorescence of CFB with patient serum was calculated accordingly. Measurements were 
carried out on Beckman Coulter FC500 flow-cytometer and analysis on Cell-Quest and 
FlowJo software. Gates were based on dot-plots of untreated bead populations. Median 
fluorescence of 10,000 events was recorded and corrected for bead auto-fluorescence. 
Standard curve was fitted with variable-slope sigmoidal dose-response function. 
Transferrin Saturation 
TfSat was determined by the urea-gel method24 with band quantitation using Scion Image 
software, normal reference range 16-56% (mean 36%). 
Routine blood test results and standard of medical care monitoring 
Haematology tests: FBC and red cell indices, reticulocytes, NRBC, serum ALT, bilirubin, 
and ferritin were performed routinely in hospital laboratories, sTfR was measured using 
ELISA (R&D Systems). 
Liver iron content (LIC) was obtained from liver T2*25 or liver R2 Ferriscan26, and cardiac 
iron content (CIC) obtained from cardiac T2*27. Medical records review provided 
information about chelation therapy, transfusion, and splenectomy status. 
Statistics 
The data was presented descriptively using mean±standard deviation (SD) or median± 
interquartile range (IQR) where appropriate, differences between subgroups were calculated 
using Wilcoxon test or paired t-test, dependent on distribution assumptions. 95% confidence 
interval (CI) follows slope and Spearman or Pearson correlation coefficient value in brackets. 
Graphpad Prism Ver. 6.0 plots were used for slope comparison and Bland-Altman plots28 to 
illustrate agreement between methods. A p<0.05 was deemed statistically significant. 
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Results 
Correlations, distributions and agreement between NTA-NTBI and bead-NTBI were first 
examined. The TfSat effects on measured values were compared, followed by the effects of 
chelation therapy, erythropoiesis, storage iron and splenectomy status on NTBI measured by 
both methods.  
Correlation and agreement of the two assays in all samples  
There was a medium-strong correlation between bead-NTBI and NTA-NTBI for all samples 
(Fig 1A). Because negative values were obtained in the NTA assay, the graph was re-plotted 
treating all negative values as zero (Fig 1C). In Bland-Altman analysis (Figs 1B,1D), the 
differences between methods notably increased at mean NTBI>2.5µM being even greater 
above mean values of 4µM. For mean values between <1 and 4µM the bias is not constant, 
being negative at <0µM (NTA method less than bead method) and positive between 0 and 
2µM (bead higher than NTA). Treating negative values as zero does not improve agreement 
(Fig 1D), suggesting that negative values are not the main reason for lack of agreement.  
The distribution of NTBI values by the two methods 
The NTBI distributions for both methods differ considerably between the assays (Fig 2A). 
With the NTA-NTBI (black) there is a clear population of negative values that is absent with 
the bead-NTBI (red). There is then a second population of positive NTA values 
(mode=1.5µM) that is absent with the bead-NTBI where the mode=0µM. Finally there is a 
long positive tail of high bead-NTBI up to 14µM that is absent with the NTA method. 
Further analysis below aims to determine the meaning of these distributional differences.  
Relationship of TfSat to NTBI values by the two methods 
NTBI values are related to TfSat by NTA assay but not bead assay. The relationship of NTBI 
values by both methods to TfSat is presented in the inset of Fig 2A. TfSat has a strong 
relationship to the NTA-NTBI over its negative range, but not to the bead-NTBI. In 
particular, the NTA-NTBI values fall with decreasing TfSat, unlike with the bead assay, with 
the NTA-NTBI becoming negative for TfSat<80%, but no such effect is seen with the bead 
method, which confirms previously published results on a smaller group of patients18. 
Because of the relationship of NTBI to TfSat by the NTA method and not the bead method, 
we examined the distribution of TfSat shown in Fig 2B for the bead-NTBI (left) and NTA-
NTBI (right) for samples where positive (red) or negative (black) NTBI values were 
obtained. It appears that whereas with the bead-NTBI TfSat has a similar (p=0.84) 
distribution for patients with positive or negative NTBI values, by contrast the negative 
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NTA-NTBI are largely confined to patients with TfSat<60% and the positive values to 
patients with TfSat>80% (p<0.0001). This supports the relevance of low TfSat to negative 
NTA-NTBI but not bead-NTBI values.  
 
Relevance of high TfSat to false-positive values with NTA assay. ‘True-negative’ bead-NTBI 
values (below ULN=0.68µM i.e. 3xSD above normal control mean=−0.1µM, SD=0.26µM, 
marked as dashed line in Fig 1A) were plotted against NTA-NTBI with the point size 
reflecting TfSat (Fig 2D, note Figures 2C,D are derived from Figure 1A). Positive NTA-
NTBI associates exclusively with high TfSat while negative NTA-NTBI almost exclusively 
with low TfSat (93±11.3% vs 41.5±18.2%, p<0.0001). This means that the positive values by 
the NTA method that are negative by the bead method associate with high TfSat and are 
‘false-positive’. This is consistent with iron being stripped off holotransferrin by NTA and 
not by CP851 (discussed). In contrast, no such distributional TfSat differences were seen 
between the negative and positive bead-NTBI values (on both sides of the red dotted line, 
Figs 2B,D). It is also possible that for other NTA-NTBI assays (N3 in the round robin18, or 
using Co or Mn blocking29) the relationship with the TfSat may be different.  
 
Relevance of low TfSat to false-negative values with NTA assay. The NTA-NTBI values were 
plotted against ‘true-positive’ bead-NTBI values (above ULN, Fig 2C, mark the range 
change on the x-axis in Fig 2C vs 2D) with the point size reflecting TfSat. It appears that the 
‘true-positive’ bead-NTBI is also typically positive by the NTA method only when associated 
with high TfSat. In the small number of values where the NTA-NTBI is negative, TfSat is 
low. Thus ‘false-negative’ NTA-NTBI values occur only in the presence of apotransferrin.  
Relationship of chelation therapy and NTBI values by both methods 
The presence of iron-chelate complexes or iron-free chelator, could in principle influence the 
assay behaviour in vitro 17,23,30. We examined these potential effects by comparing values in 
regularly chelated patients with those not receiving chelation. Both NTBI assays are plotted 
for chelated and un-chelated patients in Fig 3A. The range of values differs in the upper (no 
chelation) and lower panels (recent chelation), particularly for the bead-NTBI (red), where 
there is a ‘tail’ of high values (5-15µM) in chelated patients (Figs 3B,D). In principle, this 
could represent iron-chelate complexes detected as bead-NTBI. With the NTA-NTBI (black), 
the difference between chelated and un-chelated patients is subtler, but it appears that the 
proportion of patients with negative values decreases while that of patients with slightly 
positive values (up to 2µM) increases on chelation (Figs 3B,E). This could again represent 
the effects of iron-chelate complexes on the assays.   
In order to investigate this in more detail, the values obtained with both assays were plotted 
for patients on different chelation regimens (Figs 3F,G,H,I). Notably, values obtained on the 
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same samples with the bead assay (max. 15µM) are about 3-fold higher than with the NTA 
assay (max. 5µM) for deferiprone or combination (desferrioxamine+deferiprone) treated 
patients but not for deferasirox, where bead-NTBI values are actually lower than NTA-NTBI. 
Patients receiving desferrioxamine usually show about 2-3-fold higher values with the bead 
assay than the NTA-NTBI. NTBI levels correlated within the desferrioxamine (0.47 (0.01, 
0.77), p=0.05), and the deferiprone (0.62, (0.34, 0.81) p=0.0003) groups, but without 
agreement of absolute values, while in the deferasirox patients correlation was absent.  
Differences in patient sampling on deferasirox and deferiprone offer partial explanation. All 
patients receiving deferasirox had a 72h chelation washout, strictly observed before sampling, 
making the presence of the contaminating iron-deferasirox complexes unlikely. By contrast, 
in most of the deferiprone-treated patient samples, where 72h washout was not observed, the 
iron-chelate complexes would be expected to be present17,23. It appears that the complexes of 
deferiprone are more readily detectable as bead-NTBI than NTA-NTBI but different 
incubation times within the assay procedure are probably partly responsible for it. The 
detection of high levels by the bead assay in 2 patients on desferrioxamine (Fig 3G) is not 
predicted from in vitro evaluation of the bead assay23 and is difficult to explain unless 
patients were taking deferiprone.  
Other factors affecting relationships between assays 
Using univariate analysis, we investigated the effects of diagnoses, transfusion status, 
erythropoiesis (by sTfR), splenectomy, and storage iron, on the levels of NTBI by both 
assays. There was no relationship between NTBI and diagnoses, but both NTBI methods 
were differentially affected by high erythropoietic status, splenectomy and high iron storage 
(as detailed in Supplementary Material: Subgroup univariate analysis, Table S3, Figs S4, S5, 
S6, S7). 
Multiple regression 
Multiple linear regression models were built to test which predictors explain differences 
between the NTA-NTBI and the bead-NTBI. The same or additional predictors may resurface 
as relevant when the absolute difference (bias) between methods is modelled and this was 
attempted as a control analysis. Furthermore, we have modelled transferrin saturation using 
the same set of potential predictors as for the other models (Table II). The bead-NTBI model 
explained 25% of the variability in NTBI using TfSat, splenectomy, and DFO+DFP as 
positive predictors. The NTA-NTBI model explained >75% of the variability in NTBI, with 
TfSat, splenectomy as positive, and sTfR as negative predictors. The bias model, i.e. the 
difference CP851-NTBI less NTA-NTBI, was predicted negatively by TfSat and DFX, and 
positively by splenectomy, DFO+DFP, chelation (yes/no), and “normal”, in a model 
explaining 24% of the NTBI variability. The TfSat model explained 42% of the NTBI 
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variability using thalassaemia, Eβ-thalassaemia, MDS, CSA, DBA, and SF as positive 
predictors.  
Discussion 
This study examined a range of iron-overloaded patients with and without iron chelation, 
which allowed comparison of the established NTA-based NTBI assay (NTA-NTBI) with a 
novel fluorescent bead-based assay (bead-NTBI) under a wide range of clinical conditions. 
Overall, while significant correlations exist between both methods, absolute values differ 
with wide 95% limits of agreement, consistent with the recent round robin of NTBI assays18. 
Here, by comparing values in a large number of iron-overloaded patients, we examine how 
both assays are differently affected by identifiable variables. These are relevant to the 
application and interpretation of both NTBI assays in specific patient populations. Two 
systematic differences between the assays have been identified. Firstly, the NTA-NTBI is 
highly affected by TfSat, leading to under-estimations at low TfSat and over-estimation once 
transferrin is saturated. By contrast, the bead-NTBI is less dependent on either high or low 
TfSat. Secondly, while both assays give increased NTBI values in recently deferiprone-
treated patients, due to detection of chelate-iron complexes, this effect is more pronounced 
with the bead-NTBI, leading to a further lack of agreement between the two assays.  
 
Inspection of the NTBI distribution histograms for both assays, combined with the 
knowledge of the contrasting chelating properties of NTA and the hexadentate CP851 used in 
the bead method, provides insight into why agreement is not high. With the NTA-NTBI, two 
major peaks are seen, first centring on -2.5µM, and the second peak on 1.5µM skewed 
rightwards. With the bead-NTBI these peaks are essentially absent with most low values 
clustered around zero and with a much more pronounced right skew for positive NTBI. These 
differences are consistent with the known properties of the ‘capture’ mechanisms of the assay 
chelators. Negative NTBI values obtained with the NTA method have been attributed to 
shuttling of iron present in 80mM NTA onto apotransferrin during the initial incubation2,31,32. 
This shuttling iron donation effect, due the greater stability of the hexadentate bead chelators, 
is absent in the bead method23. 80mM NTA not only donates chelated iron to iron-binding 
apotransferrin sites, but also removes iron from holotransferrin in a time- and concentration-
dependent manner3, so that at 30 minutes 80mM NTA mobilised 1-2% of transferrin iron 
(physiological concentration, TfSat=50%). This represents 0.35-0.7µM transferrin-bound 
iron potentially detected as ‘NTBI’ but could be as much as 1.4µM with TfSat=100% in our 
patients. Others noted similar effects33,34. 
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The impact of such high iron removal from transferrin has not been previously characterised 
and here the comparison with the bead method, where iron is not stripped from 
holotransferrin (<0.2%) by the hexadentate chelator23, demonstrates this effect more clearly. 
Given the robustness towards transferrin of the bead-assay, it can be used as a reference in an 
attempt to examine transferrin dependence of the NTA-method. Closer inspection of the 
normal and pathological bead-NTBI distributions suggests a cut-off above which values can 
be regarded as ‘true-positive’ and provides supportive evidence for the mechanisms 
underlying ‘false-positive’ and ‘false-negative’ values obtained with the NTA assay. With the 
bead-NTBI, values centring in the narrow dominant peak around the mode -0.04µM  (Fig 
2A) are likely to represent an absence of true NTBI, given the comparable spread around the 
mean of the normal serum samples (-0.1±0.26µM with ULN of 0.68µM mean+3SD, 
SD=0.26µM, Figs 2A,S5K). Bead-NTBI values >0.68µM are therefore likely to represent 
‘true-positive’ NTBI. Clearly ‘false-negative’ values by the NTA method would then be 
those negative values obtained when the bead assay gives positive values >0.68µM. When 
this was checked, all the ‘false-negative’ NTA values occurred in samples with non-saturated 
transferrin (45, 18, 48%, Fig 2C) where the predicted percentage of apotransferrin, that can 
act as acceptor for iron shuttled by NTA, approaches 30%, 65% and 28% respectively35. By 
contrast, ‘false-positive’ NTA-NTBI would be those positive values that correspond to bead-
NTBI<0.68µM. All such ‘false-positive’ NTA values had highly saturated transferrin (mean 
93%, range 62-100%) supporting the concept that such ‘false-positive’ NTBI values are 
obtained from the scavenging of iron from highly saturated transferrin.  
 
The second factor, contributing to differences between both assays, is the effect of iron 
chelators or their iron complexes. With the NTA-NTBI, iron-free chelators present in plasma 
can act as acceptors for NTA-bound iron, potentially leading to the NTBI 
underestimation31,32. This donation can be blocked in the NTA assay by adding an excess of 
aluminium to samples before processing 30,32. This is not a problem for the bead-NTBI, as the 
greater stability of the CP851-iron complex prevents iron donation to iron-free chelators in 
samples23. The iron complexes of some chelators can also potentially interfere with the NTBI 
determination: with the NTA-method, the deferiprone-iron complexes are detected as ’NTBI’ 
up to 1 week following drug cessation17. In principle, the bead assay can also detect such 
complexes of deferiprone23, and indeed our findings here suggest that these are detected to a 
greater extent than with the NTA assay (Figs 3G,H,I).  
 
Due to the high stability of ferrioxamine (1:1 iron(III):desferrioxamine) the bead-assay 
removes only negligible amount of iron from DFO-iron complexes23. Given this observation, 
it is difficult to explain the presence of two outliers in Figure 3G and perhaps the iron-
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binding DFO metabolites should be considered. In the deferasirox-treated patients, NTBI is 
lower than in the other chelators using both assays but especially with the bead-assay, with 
values <1µM (Fig 3F).  This may reflect superior NTBI removal with deferasirox or that 
patients in this group had 72h washout from chelators, allowing full clearance of deferasirox-
iron complexes. These complexes may clear more rapidly than those of deferiprone which are 
measureable >1 week after the last chelation dose17. Thus in patients who are on regular 
chelation therapy, interpretation of NTBI values needs to be made with reference to the 
timing of sampling, particularly with the bead-assay which has high affinity for iron-
deferiprone and iron-deferasirox complexes23.  
 
Clinical factors potentially affecting the detection levels of both NTBI assays were examined. 
Underlying diagnoses in themselves did not show significant differences between assays 
(Table II) but the extent of erythropoiesis did (Fig S7A): higher sTfR levels (and hence 
greater erythropoiesis and iron removal from transferrin) reduce NTA-NTBI, but not bead-
NTBI values. As lower TfSat associates with decreased NTBI values due to NTA shuttling 
iron onto transferrin, clearance of transferrin-bound iron by enhanced erythropoiesis may 
increase iron shuttling by NTA and hence lower measured values. Negative prediction of the 
bias by TfSat suggests that the methods are differentially affected by TfSat, consistent with 
the methodological dependence of the NTA method on TfSat where NTA strips iron from 
transferrin, with NTBI overestimation rendering the bias lower. Likewise DFX negatively 
predicts the bias because it affects only the bead-NTBI (Fig 3F), and this is a key issue we 
are currently investigating. Normal status increases the bias by rendering NTA values 
negative (ApoTf). Chelation increases the difference because it increases the bead-NTBI 
more than the NTA-NTBI when detecting deferiprone-iron complexes. Splenectomy predicts 
NTBI by either method using multivariate analysis and also associates with higher NTBI (by 
0.5 or 1.3µM, Table II). That splenectomy predicts bias is interesting while at the same time 
being a positive predictor of both methods separately, because it implies that bead assay 
detects more NTBI in splenectomised patients rather than that the NTA method detects less 
(Fig S7B), suggesting it differentially affects the manner in which both methods may detect 
NTBI (splenectomy-dependent NTBI speciation differences). Higher NTA-NTBI in 
splenectomised TI patients was reported36, as was a greater risk of myocardial iron deposition 
post-splenectomy37. The mechanism for higher NTBI post-splenectomy is unclear but we 
suggest may relate to erythrocyte destruction being diverted from the spleen to the bone 
marrow. With relatively hypoxic bone marrow environment, oxidation from Fe2+ to Fe3+ will 
have slower kinetics, hence slower iron binding to transferrin, and greater propensity to 
plasma NTBI formation. Similarly, higher levels of iron overload (SF or LIC) are associated 
with higher bead-NTBI than NTA-NTBI values, suggesting the bead method may detect 
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some iron species associated with iron overload that are relatively unavailable for capture 
using the NTA method.  
Unlike the NTBI values by either method, the TfSat is notably predicted by diagnoses and 
ferritin in our cohort. In the explanation of the ferritin effect on TfSat but not on NTBI (the 
latter also reported recently18), we distinguished plasma iron compartment into the transferrin 
part, changing dynamically below 100% (TBI), and into NTBI part, typically present when 
transferrin is 100% saturated (TfSat not changing dynamically anymore). This means that 
ferritin as a predictor of TfSat marks the independent effect of the degree of tissue iron 
overload on the changes in the transferrin part of plasma iron compartment (i.e. TfSat 
increases when ferritin increases), but such independent effect on the level of NTBI, once 
TfSat is saturated, is absent. In other words if NTBI is considered in a continuum with TBI 
above the saturation point of Tf, it is evident that that plasma iron above the saturation point 
of Tf (NTBI) does not associate with ferritin (and therefore with iron overload) while the 
plasma iron on transferrin does. This is very interesting to us because it may suggest that 
regulation of serum iron varies by compartment: NTBI is less dependent for its generation 
and persistence on iron overload per se, and likely more dependent on other factors such as 
those that determine its removal rather than generation (tissue uptake – erythroid, hepatic)5,38. 
Finally, that sTfR does not predict TfSat but does negatively predict NTBI implies that the 
rate of transferrin off-loading in the marrow may affect the NTBI compartment without 
apotransferrin being detected peripherally38. 
 
In conclusion, we have identified that the TfSat in the blood sample affects values obtained 
with the NTA assay to a greater extent than with the bead assay. This results from iron 
donation to apotransferrin by NTA and/or stripping of iron from saturated transferrin by 
NTA. Neither of these effects is significant with the bead assay, which may therefore be more 
specific for true NTBI determination. These findings are consistent with first principles, 
namely differential access to transferrin iron of both methods, but other mechanisms may be 
involved, which require further systematic study. The presence of iron-chelate complexes in 
patients on chelation, particularly with deferiprone, increases values obtained with the bead 
assay more than with the NTA assay. Recent chelation history (minimum a week before 
blood sampling) needs accounting for when interpreting NTBI values obtained with either 
method. Other differences between the assays regarding the effects of splenectomy, levels of 
iron overload and endogenous erythropoiesis are consistent with both assays differentially 
accessing NTBI pools that vary with these clinical variables. Future work will need to 
identify whether NTBI values obtained with the bead assay are more clinically predictive of 
trends, such as myocardial iron deposition, than with the NTA assay. The effects of sample 
timing in relation to currently available chelation therapies need to be further defined with 
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both assays. We recommend using both methods in NTBI research since the NTA-NTBI and 
the bead-NTBI do not detect exactly the same species of NTBI, and that further research is 
necessary to describe NTBI speciation in greater detail before a recommendation can be 
made (if at all) which method should the researchers rely on.  
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Figures legends 
Figure 1. Comparison of NTA and beads method for NTBI measurement. (A) NTA and 
beads (CP851) methods plotted for all samples using original scale. Correlation coefficient 
r=0.57 (0.44-0.68) p< 0.0001 (B) Agreement shown using Bland-Altman analysis of 
difference (∆NTBI=NTA-CP851) vs mean of the two methods on data from panel A with 
bias -1.21±2.25µM and 95% LoA (limits of agreement) from -5.6 to 3.2µM. (C) Both 
methods for NTBI measurement plotted as in panel A but with negative values by both 
methods shown as zero (absent NTBI) Correlation coefficient r=0.6 (0.48-0.7) p<0.0001. (D) 
Agreement shown using difference vs mean Bland-Altman analysis of data in panel C, bias -
0.56±2.1µM, 95% LoA -4.68 to 3.56µM. 
 
Figure 2. Distribution of CP851-NTBI, NTA-NTBI, and transferrin saturation values 
with analysis of false-positive and false-negative NTA-NTBI values.  (A) Comparing 
frequency distribution histograms of CP851-NTBI (red) and NTA-NTBI (black) in 135 pairs; 
frequency (number of values) of NTBI per interval of 0.5µM(bin size) is shown. Inset shows 
relationship between NTBI level and urea-gel TfSat for both methods: CP851-NTBI (red) 
and NTA-NTBI (black); best-fit linear regression slope differences (p<0.0001) with 100% 
TfSat points excluded from regression. (B) Plots of Tf saturation on x-axis (in 10% 
increments, bin center) against frequency of TfSat observations (y-axis) for NTBI values < or 
> 0µM. Left panel shows bead method and right panel NTA method. The TfSat distributions 
for NTBI values > 0µM are significantly different from those under 0µM by the NTA method 
only (Mann-Whitney test); at low TfSat negative NTBI values are significantly more likely 
by NTA method and at high TfSat positive NTBI values are more likely by NTA method. 
These differences are not apparent by the beads method. (C) Plot of NTA-NTBI values vs 
true-positive bead-NTBI values (above ULN=0.68µM - dashed line in Figure1A), size of the 
point reflects TfSat. Data in red-shaded box (below ULN) is shown in panel D. (D) Plot of 
NTA-NTBI vs true-negative bead-NTBI (red-shaded box in panel C corresponds to the data 
to the left of the dashed line in Figure 1A) with point size reflecting TfSat. Mean TfSat for 
NTA values >0µM was 93%, 19/36 were 100%, range 62-100%, median, 25th and 75th 
percentile: 100, 91, 100%. Mean TfSat for NTA values <0µM was 41.5%, 1/46 was 100%, 
range 11-100%, median, 25th and 75th percentile: 39.5, 31.5, 46%. 
Figure 3  
Figure 3. Effect of chelation on method agreement. (A). Comparison of NTBI distributions 
in patients not chelated (upper panel) and chelated (lower panel), red symbols show the bead 
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CP851 assay and black symbols the NTA assay. (B) Comparison of NTA method vs bead 
method in patients with (black) and without (red) chelation, of the outliers marked only the 
chelation ones were excluded from analysis in CDE. (C) Comparison of TfSat distributions 
in chelated and unchelated patients seen in B, Mann-Whitney test. (D) Comparison of 
CP851-NTBI in cheated and unchelated patients seen in B, Mann-Whitney test (E) 
Comparison of NTA-NTBI in chelated and unchelated patients seen in B, Mann-Whitney 
test. (F) NTA method vs bead method in patients on deferasirox, no correlation (ns) (G) NTA 
method vs bead method in patients on desferrioxamine, correlation coefficient r=0.47 (0.01-
0.77), p=0.05. (H) NTA method vs bead method in patients on deferiprone, correlation 
coefficient r=0.63 (0.34-0.81), p=0.0003. (I) NTA method vs bead method in patients on 
combination therapy of deferiprone and Desferrioxamine, correlation coefficient r=0.78 (0.3-
0.95), p=0.0076. 
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Tables 
Table I.  
Table I. Patient diagnoses, patient number correlation within diagnoses and NTBI differences 
for groups with n>5. 
Diagnosis n Correlations1 Grouped2 NTBI comparison3 
Eβ-Thalassaemia (Eβ-thal) 44 0.68 (0.48-0.81)*** n=84, r=0.63  
(0.49-0.74)*** 
1.3 vs 1.0*** 
β-Thalassaemia Major (β-TM) 24 0.72 (0.44-0.87)*** 0.84 vs 0.82** 
Thalassaemia Intermedia (TI) 11 0.5 (-0.14-0.85) ns -0.06 vs 1.54 ns 
Bart’s Hb 3 N/A N/A 
α-Thalassaemia 2 
Hereditary HFE Haemochromatosis (HH) 9 0.64 (-0.04-0.92) ns n=38, r=0.66  
(0.47-0.79)*** 
-0.04 vs -1.67 ns 
Sickle Cell Disease (SCD) 6 0.54 (-0.36-0.92) ns -0.07 vs -2.11 ns 
Congenital Sideroblastic Anaemia (CSA) 5  
 
 
 
 
 
N/A 
 
 
 
 
 
 
 
N/A 
Myelodysplastic Syndrome (MDS) 3 
Diamond-Blackfan Anaemia (DBA) 2 
Pyruvate Kinase Deficiency Anaemia  2 
Aceruloplasminaemia 2 
Ferroportin Disease 2 
Red Cell Aplasia 1 
Sickle-E-β-Thalassaemia (SCD) 1 
Congenital Dyserythropoietic Anaemia  1 
β-Thalassaemia-Hb Malay anaemia 1 
Haemolytic Anaemia 1 
Spherocytosis 1 
Atransferrinaemia 1 
Normal Volunteers 13 0 (horizontal line)  -0.1 vs -2.75*** 
1 Spearman correlation coefficient between NTA-NTBI and bead-NTBI, (95% CI), p value.  
2 Spearman correlation coefficient between NTA-NTBI and bead-NTBI, (95% CI), p value in all thalassaemia and all non-
thalassaemia diagnoses.  
3
 Comparison of median bead-NTBI vs NTA-NTBI, [uM], Wilcoxon test  
p value <0.0001***, <0.001**, <0.01*, ns, not significant. 
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Table II 
Table II. Multiple regression models for NTA-NTBI, CP851-NTBI, bias (CP851-NTA), and 
Transferrin Saturation.  
model NTA-NTBI CP851-NTBI  bias TfSat 
Adjusted r-square 0.75*** 0.26*** 0.24*** 0.42*** 
n 101 120 117 100 
Constant -3.890.27*** -1.370.59* 2.160.62** 42.175.01*** 
TfSat 0.0560.003 (0.86)*** 0.0280.007 (0.3)*** -0.0260.007 (-0.34)***  
Splenectomy yes=1 0.510.2 (0.13)* 1.320.47 (0.23)** 0.860.41 (0.18)*  
Thalassaemia yes=1    31.195.67 (0.52)*** 
Eβ-thal yes=1    11.64.75 (0.21)* 
MDS yes=1    42.115.3 (0.21)** 
CSA yes=1    42.510.4 (0.33)*** 
DBA yes=1    47.815.2 (0.24)** 
SF [ug/L]    0.0060.001 (0.31)*** 
sTfR [nM] -0.0030.001 (-0.12)*    
Chelation yes=1   1.250.45 (0.27)**  
DFO+DFP yes=1  2.290.8 (0.23)** 1.590.71 (0.19)*  
DFO yes=1     
DFX yes=1   -1.810.61(-0.26)**  
Normal yes=1   1.420.7 (0.19)*  
Empty cell indicates that predictor was not significant in a particular model. Statistics for 
predictors (bold italics) are given as absolute regression coefficient, its standard deviation in 
subscript, adjusted regression coefficient in brackets, followed by significance of the 
predictor (***<0.0001, **<0.001, *<0.05). All other predictors insignificant (LIC, cardiac 
T2*, SGOT, SGPT, Ret, NRBC, Plt, WBC, Hb, Hct, MCV, MCH, MCHC, bilirubin, 
transfusion). Multiple linear regression on SPSS Version 22 was used.  
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Brief Commentary 
 
Background 
NTBI is increasingly understood as a multi-speciated plasma iron pool, regulated 
separately from transferrin-bound iron and implicated in the complications of iron 
overload. The established NTA-NTBI method is not optimal for distinguishing 
transferrin bound iron from NTBI.  
 
Translational significance 
Here we compared a novel fluorescent bead method with the NTA method, across 
clinical diagnoses.  The NTA assay underestimates or overestimates NTBI at low or 
high transferrin saturations respectively, which the bead assay being robust to effects 
of transferrin does not. The greater specificity of the bead assay should clarify links 
between raised NTBI levels and their clinical consequences. 
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Supplementary data 
Subgroup univariate analysis 
NTBI by underlying diagnoses 
The relationship between both assays was broadly similar across different patient diagnoses 
although median bead-NTBI values were typically higher than NTA-NTBI for Eβ-thal, β-
TM, SCD, HH and healthy controls (Fig S4, Table I).  Significant correlations but poor 
agreement between both NTBI methods were seen for Eβ-thal, β-TM and all thalassaemias, 
with negative values by both methods treated as zero (Fig S5, Table S3).  Other diagnoses 
were not sufficiently represented to draw correlation or agreement conclusions, however in 
non-thalassaemic group as a whole the correlation was significant (Table I). Normal control 
samples neither correlated nor agreed between the two assays but their bias could be 
corrected for (Fig S5L).  
Transfusion 
In transfused patients both methods correlated but non-transfused patients correlation was 
weak. Slopes were significant in both groups but only intercepts differed (Table S3). 
Significant effect of transfusion seems to be limited to high TfSat as only samples with 
TfSat>90% show significant positive slope among transfused patients (Fig S6). Bead-NTBI 
was higher than NTA-NTBI in transfused and untransfused patients (Table S3).  
Erythropoiesis  
High and low erythropoietic states were judged by soluble transferrin receptor (sTfR) levels 
above (high) and below (low-normal) 28.1nM (ULN). NTBI methods correlated, the slopes 
were significantly positive but differed from one another, for high and low-normal 
erythropoietic states. The NTA assay detected less NTBI relative to the bead assay for 
patients with high erythropoiesis compared to those with low-normal levels of erythropoiesis 
(Table S3, Fig S7A). Since a high erythropoietic rate will increase iron clearance from 
transferrin, this is predicted to free up iron binding sites on transferrin thus increasing iron 
shuttling onto these sites and hence lower levels with the NTA assay.  
Splenectomy 
In patients with and without splenectomy, the methods correlated well with positive slopes 
that differed significantly: bead-NTBI being higher, and the difference between methods 
being greater in splenectomised than un-splenectomised patient (Fig S7B, Table S3). 
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Storage iron 
For high- and low-ferritin patient groups (above or below 1500 µg/L), methods correlated 
well with significantly different positive slopes. There was greater discrepancy between 
NTBI levels in the high ferritin than the low ferritin group  (Fig S7C, Table S3): for similar 
CP851-NTBI values, NTA method gives lower NTBI values in the former and higher in the 
latter group above about 2 µM bead-NTBI threshold. Methods were also compared in LIC 
groups below and above 12mg/gdw (SF=1500ug/L corresponds in our study to 
LIC=12mg/gdw) showing medium correlation and significantly different positive slopes. In 
high LIC group, discrepancy between methods was greater (Fig S7D, Table S3). NTBI 
differences were insignificant on direct comparison: not all patients had LIC available (n=35 
vs n=109 for ferritin), so comparison may be underpowered to detect differences. Taken 
together these findings show that at high storage iron (LIC or SF) the extent to which bead-
NTBI values exceed NTA-NTBI is increased.  
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Table S3 
Table S3. Subgroup analysis: correlations, slope comparison and NTBI differences between 
transfusion, erythropoiesis,  
splenectomy, storage iron and chelator subgroups (p-value <0.0001***, <0.001**, <0.01*, 
ns, not significant). 
Subgroup1 Correlation2 Slope3  test4 NTBI comp.5 
all samples 0.61 (0.49-0.71), ***   1.5±2.59µM vs 
0.94±1.13µM, * 
transfused 0.57 (0.4-0.7), *** 0.31 (0.21-0.41), ***  
ns, 
int** 
2.04±2.99µM vs 
0.76±1.56µM, *** 
untrasfused 0.31 (0.02-0.55), * 0.83 (0.05-1.6), * 0.14±0.71µM vs -
0.83±1.91µM, ** 
high sTfR 0.63 (0.48-0.74), ***  0.25 (0.18-0.31), ***  
* 
1.8±2.9µM vs 
1.1±1.16µM, * 
low-normal 
sTfR 
0.6 (0.28-0.8), ** 0.83 (0.36-1.29), ** 0.44±0.83µM vs 
0.7±1.13µM, ns  
splenectomy 0.5 (0.24-0.69), ** 0.14 (0.06-0.21), **  
*** 
2.97±3.7µM vs 
1.26±1.02µM, ** 
no 
splenectomy 
0.68 (0.55-0.79), ***  0.44 (0.33-0.54), *** 0.84±1.7µM vs 
0.73±1.1µM, ns 
SF 
>1500ug/L 
0.55 (0.32-0.72), *** 0.17 (0.1-0.25), ***  
* 
0.82±1.66µM vs 
0.71±1.03µM, ns 
SF 
<1500ug/L 
0.65 (0.47-0.78), *** 0.41 (0.280.54), *** 2.83±3.45µM vs 
1.49±1.07µM, *  
LIC>12 0.77 (0.48-0.91), *** 1.05 (0.6-1.49), ***  
* 
0.45±0.96µM vs 
0.86±1.31µM, ns  
LIC<12 0.66 (0.24-0.87), * 0.42 (0.14-0.69), *  0.63±1.67µM vs 
1.19±1.06µM, ns 
1
 conditions where bead-NTBI and NTA-NTBI were compared, 2 Pearson correlation 
coefficient (95% CI), p value, 3 Slope (95% CI), p value,  
4
 comparison of slopes p-value or when ns, the intercept (int) comparison p-value,  5 mean 
NTBI comparison  CP851 vs NTA (95% CI), t-test p 
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Figure S4 
 
Figure S4. Box and whisker plot (range) of NTBI in healthy controls and 
various conditions of iron overload using a standard analytical method (NTA-
NTBI) and the proposed bead-based NTBI method. 
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Figure S5 
 
Figure S5. Comparison and Bland-Altman analysis of agreement of NTA and 
CP851-NTBI methods in different diagnosis groups. Negative values by both 
methods have been treated as zero. (A-B) all diagnoses; slope p<0.0001. (C-D) 
beta-Thalassaemia Major; slope p<0.0001. (E-F) E-beta-Thalassamia; slope 
p<0.0001. (G-H) thalassaemia intermedia; slope not significant. (I-J) all 
thalassaemias; slope p<0.0001. (K-L) normal volunteers; slope not significant. All 
Bland-Altman analyses show lack of acceptable agreement except for the normal 
samples where the low scatter systematic bias could be corrected for using the 
formula (239.1±35.12[%]*avgNTBI[uM]+527.3±50[%])(27). 
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Figure S6  
 
 
Figure S6. The effect of transferrin saturation on method agreement in transfused and 
untransfused patients. (A) Plot of both NTBI methods in transfused (black) and 
untransfused patients (red). (B) Plot of both NTBI methods in untransfused patients (red in 
panel A). Samples with TfSat>90% are now shown in red and those with TfSat<90% in 
black. (C) Both NTBI methods plotted in transfused patients (black in panel A), here further 
grouped according to TfSat in sample: with significant slope in TfSat>90% (red, p<0.0001) 
and insignificant in TfSat<90% (black). (D) Both methods plotted for transfused patients 
with TfSat <90% show insignificant slope (black symbols from panel E magnified).
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Figure S7 
 
Figure S7. Comparison of NTA-NTBI and CP851-NTBI methods in groups with 
different erythropoietic, spleen, ferritin and LIC status. (A) Slope comparison between 
high and low-normal erythropoietic status defined by soluble transferrin receptor: both slopes 
are significant (0.25±0.03, p<0.0001 and 0.82±0.22, p=0.001) and different (p=0.01); patients 
mean sTfR (n=117) was 93.46±68.1nM (median 88.24, IQR 30.1-133.2, range 5.38-332.5) 
(B) Slope comparison between patients with and without splenectomy: both slopes are 
significant (0.14±0.04, p=0.0005, and 0.44±0.05, p<0.0001) and different (p<0.0001). (C) 
Slope comparison between low and high ferritin groups (1500ug/L): both slopes are 
significant (0.41±0.06 and 0.17±0.04, both p<0.0001) and different (p<0.0013). (D) Slope 
comparison in low and high LIC groups (12mg/gdw): both slopes significant (1.05±0.21, 
p=0.0001 and 0.42±0.13, p=0.006) and different (p=0.015).  
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